MARKET NEWS

Exclusive License for Croda to Commercialize SSI’s CAF® Vaccine Adjuvants
Fulcrum Therapeutics Announces Phase 3 Clinical Trial
Aravive Announces Positive Updated Data & New Biomarker Data From Phase 1b Study 
Skye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate
Pii Announces New President & Chief Executive Officer
Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma From Accure Therapeutics

  FEATURED EDITORIAL

  COMPANY PROFILE

Serán Bioscience is a science-first CDMO, recognized as a leader in materials science, formulation development, and pharmaceutical manufacturing. We utilize a foundation of physical and chemical science to design robust formulations and engineered solutions. Our science, quality systems, regulatory expertise, and customer service are second to none. Your drug is your future, and you need a CMC partner that’s as committed to your success as you are. Click here for more.

Our portfolio of formulation products includes excipients for solid, semi-solid and liquid dosage forms for small and large molecules, allowing you to formulate APIs to your exact specifications and requirements. We offer both customized manufacturing and a standard portfolio of synthetic lipids and functionalized PEGs, biodegradable polymers for sustained release of small and large molecules and functional excipients for excellent performance in tableting processes, solubility enhancement and controlled release. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Evonik Increases Global Supply of Pharma-Grade Plant-Derived Cholesterol for mRNA Vaccines & Gene Therapies

Evonik Increases Global Supply of Pharma-Grade Plant-Derived Cholesterol for mRNA Vaccines & Gene Therapies

Evonik has boosted its supply of plant-derived cholesterol, one of the most critical components for the manufacture of mRNA vaccines and gene therapies. The large-scale production of….

Aeterna Zentaris Announces Notice of Allowance for US Patent Covering AEZS-150 for the Potential Treatment of Chronic Hypoparathyroidism

Aeterna Zentaris Announces Notice of Allowance for US Patent Covering AEZS-150 for the Potential Treatment of Chronic Hypoparathyroidism

Aeterna Zentaris Inc. recently announced that its licensor, The University of Sheffield, has received a notice of allowance from the USPTO for its patent application No. 16/608,611…..

Cambrex Expands Biopharmaceutical Services Business

Cambrex Expands Biopharmaceutical Services Business

Cambrex recently announced it is significantly expanding its existing biopharmaceutical testing services business. The expansion includes 11 additional cGMP….

CDMOs Need to be Prepared for the Revision of the EU-GMP-Annex 1

CDMOs Need to be Prepared for the Revision of the EU-GMP-Annex 1

Annex 1 of the EU-GMP-Guide Manufacture of Sterile Medicinal Products is considered the most important European regulatory standard for the manufacture of sterile pharmaceutical products. The current revision will have to….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

March 16 – Drug Delivery
March 23 – Parenteral Contract Manufacturing